<DOC>
	<DOCNO>NCT00691262</DOCNO>
	<brief_summary>Objective study ass response treatment safety 0.03 % tacrolimus ( FK506 ) ointment use 6 month pediatric patient moderate severe atopic dermatitis , know responsive topical steroid .</brief_summary>
	<brief_title>Study Evaluate Response Treatment Safety 0.03 % Tacrolimus ( FK506 ) Ointment Administered Pediatric Patients With Moderate Severe Atopic Dermatitis</brief_title>
	<detailed_description>The main phase 6 month duration , follow-up phase 12 month allow collection RTT safety data period include season patient , account seasonal variability strongly affect AD course .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patient may male female ethnic group Patient age 2 year 15 year ( complete his/her 16th birthday ) suffers moderate severe atopic dermatitis ( Rajka/Langeland score least 4.5 ) . Patient know responsive topical steroid Patient 's legal representative give write informed consent . If patient capable understanding purpose risk trial write informed consent obtain patient well . Female patient childbearing potential must agree maintain adequate birth control practice trial period first four week end study Patient meet follow washout criterion : Topical corticosteroid Systemic corticosteroid ( treatment AD ) Systemic nonsteroidal immunosuppressant ( e.g . cyclosporine , methotrexate ) Other investigational drug Light Treatments ( UVA , UVB ) Patient taken/patient legal representative agree patient take complete study period medication therapy prohibit protocol Patient genetic epidermal barrier defect Netherton 's syndrome generalise erythroderma Patient pregnant breastfeed Patient skin infection affect ( treat ) area Patient know hypersensitivity macrolides general , Tacrolimus excipient ointment Patient simultaneously participate drug trial le 28 day pass end previous trial one Any form substance abuse ( include drug alcohol abuse ) , psychiatric disorder condition , opinion investigator , may invalidate communication investigator Patient know HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Prograf</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>FK506</keyword>
	<keyword>Tacrolimus ointment</keyword>
</DOC>